Intervention and control
allergic reaction
EVENT, ALLERGIC REACTION
Patients allocated to the intervention group will be asked to consume a clear protein powder shake containing 20 g of whey protein per serving daily dissolved in 200 mL of water during the first 6 months after surgery. Patients allocated to the control group will be asked to consume a clear placebo shake daily during the first 6 months after surgery. The placebo shake contains maltodextrine and is isocaloric with the protein shake. The placebo shake looks the same and has the same smell and taste. Both protein and maltodextrine are provided as a powder in single-use sachets. Study participants will dissolve the content of one sachet in 200 mL water and shake it until the powder is fully dissolved. All sachets look similarly neutral but contain a unique code. The codes are listed in the key document, indicating the content to be protein or placebo. Thus study participants are also blinded to the treatment. The allocated intervention will never be modified for a given trial participant. Discontinuing the intervention may be done at participants’ request or if unblinding is necessary due to a suspected allergic reaction to the study product. However, apart from the unlikely event of an allergic reaction, there are no anticipated harms in this low-risk trial.Product specification sheets are enclosed with this manuscript as 